IL312392A - Neutralizing monoclonal antibodies against cervaviruses - Google Patents

Neutralizing monoclonal antibodies against cervaviruses

Info

Publication number
IL312392A
IL312392A IL312392A IL31239224A IL312392A IL 312392 A IL312392 A IL 312392A IL 312392 A IL312392 A IL 312392A IL 31239224 A IL31239224 A IL 31239224A IL 312392 A IL312392 A IL 312392A
Authority
IL
Israel
Prior art keywords
sarbecoviruses
monoclonal antibodies
antibodies against
neutralizing monoclonal
neutralizing
Prior art date
Application number
IL312392A
Other languages
English (en)
Hebrew (he)
Inventor
Massimo Clementi
Nicola Clementi
Elena Criscuolo
Martina Libera
Nicasio Mancini
Sofia Sisti
Original Assignee
Ospedale San Raffaele Srl
Massimo Clementi
Nicola Clementi
Elena Criscuolo
Martina Libera
Nicasio Mancini
Sofia Sisti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ospedale San Raffaele Srl, Massimo Clementi, Nicola Clementi, Elena Criscuolo, Martina Libera, Nicasio Mancini, Sofia Sisti filed Critical Ospedale San Raffaele Srl
Publication of IL312392A publication Critical patent/IL312392A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL312392A 2021-10-29 2022-07-20 Neutralizing monoclonal antibodies against cervaviruses IL312392A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21205626.1A EP4174083A1 (en) 2021-10-29 2021-10-29 Neutralizing monoclonal antibodies against sarbecoviruses
PCT/IB2022/056706 WO2023073441A1 (en) 2021-10-29 2022-07-20 Neutralizing monoclonal antibodies against sarbecoviruses

Publications (1)

Publication Number Publication Date
IL312392A true IL312392A (en) 2024-06-01

Family

ID=78414544

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312392A IL312392A (en) 2021-10-29 2022-07-20 Neutralizing monoclonal antibodies against cervaviruses

Country Status (7)

Country Link
US (1) US20260234220A1 (cg-RX-API-DMAC7.html)
EP (2) EP4174083A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024540147A (cg-RX-API-DMAC7.html)
AU (1) AU2022374853A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235310A1 (cg-RX-API-DMAC7.html)
IL (1) IL312392A (cg-RX-API-DMAC7.html)
WO (1) WO2023073441A1 (cg-RX-API-DMAC7.html)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE062777T2 (hu) * 2020-02-26 2023-12-28 Vir Biotechnology Inc SARS-CoV-2 elleni antitestek
US20230348571A1 (en) * 2020-04-06 2023-11-02 Vanderbilt University Cross-reactive coronavirus antibodies and uses thereof

Also Published As

Publication number Publication date
JP2024540147A (ja) 2024-10-31
WO2023073441A1 (en) 2023-05-04
EP4174083A1 (en) 2023-05-03
EP4423124A1 (en) 2024-09-04
AU2022374853A1 (en) 2024-05-16
US20260234220A1 (en) 2026-08-13
CA3235310A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
HUE062777T2 (hu) SARS-CoV-2 elleni antitestek
EP4271707A4 (en) NEUTRALISING MONOCLONAL ANTIBODIES AGAINST COVID-19
ZA202205226B (en) Ri-labeled humanized antibody
IL308741A (en) Anti-SIRP-alpha antibodies
PL4214240T3 (pl) Przeciwciała anty-CCR8
GB202105110D0 (en) Anti-CD73 antibodies
GB202111905D0 (en) Antibodies
IL300142A (en) Anti-IL13Ralpha2 antibodies
HUE069403T2 (hu) Anti-PD-1 antitestek
GB202014851D0 (en) SARS-COV-2 antibodies
GB202015115D0 (en) ZIP12 Antibody
GB201911211D0 (en) Monoclonal antibodies against ambra-1
GB202105933D0 (en) Anti-IL1rap antibody
GB202008022D0 (en) Antibodies
GB202304512D0 (en) Antibodies
IL308782A (en) Antibodies
IL308100A (en) Antibodies
GB202204159D0 (en) Antibodies
GB202102227D0 (en) Antibodies
GB202313544D0 (en) monoclonal antibody
GB202208773D0 (en) Anti-SARS2-S antibodies
GB202306125D0 (en) Monoclonal antibody
IL307175A (en) IL-38 specific antibodies
GB202116709D0 (en) Antibodies
GB202115824D0 (en) Antibodies